Autoantibodies against plasma coagulation factors could be developed by some individuals
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …

Background Emicizumab is a bispecific antibody that mimics the cofactor function of
activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A …

Acquired hemophilia A and acquired von Willebrand syndrome are rare, but life-threatening
bleeding disorders that require prompt diagnosis and treatment by hematologists. Acquired …

Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant
morbidity and mortality. Although critical for disease control, there is no consensus for the …

Emicizumab is currently approved to prevent bleeding in patients with congenital hemophilia
A with or without neutralizing antibodies (inhibitors) against factor VIII (FVIII). Here, we …

Background Acquired haemophilia A is caused by neutralising autoantibodies against
coagulation factor VIII, leading to severe bleeding. Standard treatment involves …

Abstract Background About 1%–5% of acquired haemophilia A cases affect mothers in the
postpartum setting. Aims This study delineates the characteristics of this disease, specific to …

There is a dire need to develop an algorithm to improve the recognition of acquired
hemophilia A and B (AHA and AHB) in clinical practice. Initial and intensive care unit (ICU) …

Acquired hemophilia A (AHA) is a rare autoimmune disorder resulting from the formation of
neutralizing antibodies against coagulation factor VIII (FVIII). 1, 2 It is characterized by a …